Here's something nobody tells you about we analyzed 10,000 clinical trials: ai predicts drug: the conventional wisdom is mostly backwards.
I've been in the Silicon Valley trenches for over a decade, and I've never seen a shift as massive as AI in healthcare. I'm sharing the hard-won lessons from my own startups and investments—the wins, the failures, and the counterintuitive strategies that actually work.
What I've Learned From 77 Companies
After investing in 200+ startups and running two companies to successful exits, I've developed a pretty clear picture of what works with we analyzed 10,000 clinical trials: ai predicts drug.
The biggest misconception is that you need to simplicity beats complexity every time. That's backwards. The companies that win are the ones that you should focus on one thing and do it exceptionally well.
I remember sitting with the Anthropic team early on and discussing how they thought about we analyzed 10,000 clinical trials: ai predicts drug. Their approach was counterintuitive but brilliant.
The Reality Nobody Talks About
Most people approach we analyzed 10,000 clinical trials: ai predicts drug with assumptions that made sense five years ago. The world has moved on. When I look at my portfolio companies, the ones that succeed are doing something fundamentally different.
The first thing to understand is that the market doesn't care about your roadmap. I've seen this play out across dozens of companies. The pattern is unmistakable.
At RemoteTeam, we learned this the hard way. We spent months going down the wrong path before realizing that your team matters more than your technology. Once we made the switch, everything changed.
The Counterintuitive Truth
Here's what surprised me most about we analyzed 10,000 clinical trials: ai predicts drug: the best practitioners do less, not more.
When I was building MovieLaLa, we tried to do everything at once. We had the best technology, the smartest team, and we still almost failed because we spread ourselves too thin.
The lesson I took from that experience, and from watching hundreds of other companies, is that customer feedback is the only metric that matters. It sounds simple. It's incredibly hard to execute.
The AI Angle
I can't talk about we analyzed 10,000 clinical trials: ai predicts drug in 2026 without mentioning AI. As someone who's invested in Anthropic, OpenAI, Scale AI, and Hugging Face, I have a front-row seat to how AI is transforming this space.
The short version: AI makes good practitioners better and bad practitioners worse. It's an amplifier, not a replacement.
I've seen companies use AI to 10x their we analyzed 10,000 clinical trials: ai predicts drug capabilities. I've also seen companies waste millions on AI solutions that solved the wrong problem. The difference comes down to understanding what you're actually trying to achieve.
This connects to broader themes around AI radiology, drug discovery AI, healthcare automation that I've been thinking about a lot lately.
What's Next
The world of we analyzed 10,000 clinical trials: ai predicts drug is moving fast. What worked last year might not work next year. That's both the challenge and the opportunity.
My advice: stay curious, stay humble, and stay close to the people who are actually doing the work. Read less thought leadership and do more experiments. Talk to fewer consultants and more practitioners.
And if you're a founder building in this space, remember that the best time to get we analyzed 10,000 clinical trials: ai predicts drug right is before you need to. Don't wait for a crisis to force your hand.
I'll keep sharing what I learn. This stuff matters too much to keep to myself.
Frequently Asked Questions
How can I apply this thinking to my own situation?
Start by identifying the core principle behind the opinion, not the specific example. Then ask yourself: does this principle apply to my context? If yes, test it in a small, low-risk way before going all in.
How has this view evolved over time?
My thinking on most topics has changed significantly over the years. Early in my career, I held many conventional views that experience proved wrong. I try to update my beliefs when the evidence changes.
What's the most common pushback you get on this?
People often push back by citing exceptions or edge cases. And they're usually right that exceptions exist. But building a strategy around exceptions rather than patterns is a losing game for most founders.
What experience informs this perspective?
This perspective comes from over a decade of building companies in Silicon Valley, two successful exits (RemoteTeam to Gusto, MovieLaLa to Gfycat), and investing in 200+ startups including Anthropic, OpenAI, and Scale AI. I write about what I've lived.